Incb024360

Other Medications

Experimental

Not available 1 Clinical Trials

Description

Incb024360 is an investigational drug currently being studied by Incyte Corporation. It is being explored in clinical trials, including one trial for colorectal cancer. This trial is a Phase 1 study, which means it primarily focuses on determining the safety and tolerability of the drug, as well as finding the right dose. The trial involves combining Incb024360 with another drug, pembrolizumab. The specific trial (NCT02178722) aims to assess the safety, tolerability, and potential effectiveness of this combination in patients with certain cancers. The trial included patients with specific characteristics, such as BRAF mutations, MSI-H status, and PD-L1 expression levels. As an investigational drug, Incb024360 is not yet approved for treating colorectal cancer or any other condition.

Mechanism of Action

Incb024360 is being studied in combination with pembrolizumab. Pembrolizumab is an immunotherapy drug that works by blocking a protein called PD-1 on immune cells, which helps the immune system attack cancer cells. The specific mechanism of action for Incb024360 is being investigated in clinical trials. It is being studied alongside pembrolizumab, suggesting it may target a different pathway involved in cancer growth or immune response.

Side Effects

As Incb024360 is an investigational drug in early-phase trials (Phase 1) Detailed information about its side effects is still being gathered. The primary focus of Phase 1 trials is safety and determining the maximum tolerated dose. Common side effects observed in Phase 1 trials can vary widely depending on the drug and the combination used. Participants in the trial (NCT02178722) experienced side effects related to both Incb024360 and pembrolizumab. More specific side effect data for Incb024360 alone or in this combination will become available as trials progress.

Not all side effects are listed. Side effects vary by individual. Always consult your oncologist.

Clinical Trials

NCT02178722 Phase 1

Archived

Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers

United States

Quick Info

Category	Other Medications
EMA Status	Experimental
Spain Access	Not available
Clinical Trials	1

View Clinical Trials Back to Drug Glossary

Related Medications

Medical Disclaimer

This information is for educational purposes only and should not replace professional medical advice. Always consult your healthcare team before making treatment decisions.